文献速递淋巴瘤

纳武利尤单抗治疗自体造血干细胞移植失败后复发或难治性经典型霍奇金淋巴瘤:多队列单臂II期CheckMate 205试验的延长随访

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
PubMed 文献 · J Clin Oncol · 2018-03-27

这项多中心、单臂II期研究纳入243例自体造血干细胞移植(auto-HCT)失败后的复发或难治性经典型霍奇金淋巴瘤患者,按治疗史分为三个队列,均接受纳武利尤单抗3 mg/kg每2周一次治疗。中位随访18个月,总体客观缓解率为69%(95% CI,63%至75%),各队列为65%至73%,中位缓解持续时间16.6个月、中位无进展生存期14.7个月。延长随访显示缓解频繁且持久,安全性良好。

要点

  • auto-HCT失败后复发或难治性cHL患者中,纳武利尤单抗总体客观缓解率为69%(95% CI,63%至75%)。
  • 中位随访18个月,中位缓解持续时间16.6个月,中位无进展生存期14.7个月。
  • 最常见3至4级药物相关不良事件为脂肪酶升高(5%)、中性粒细胞减少(3%)和ALT升高(3%)。

核心结论

  • 延长随访显示,纳武利尤单抗在复发或难治性经典型霍奇金淋巴瘤中缓解频繁且持久,似乎具有良好安全性特征,并在广泛患者人群中显示长期获益。

研究设计与样本

  • 多中心、单臂、II期研究,纳入auto-HCT治疗失败后的复发或难治性cHL患者。
  • 按治疗史分为三个队列:未接受维布妥昔单抗(BV)者(队列A)、auto-HCT后接受BV者(队列B)、auto-HCT前后接受BV者(队列C)。
  • 共243例患者接受治疗,队列A 63例、队列B 80例、队列C 100例。
  • 所有患者接受纳武利尤单抗3 mg/kg每2周一次,直至疾病进展或不可接受的毒性。
  • 主要终点为独立放射学审查委员会评估的客观缓解率。

主要发现

  • 中位随访18个月时,40%的患者仍在接受治疗。
  • 总体客观缓解率为69%(95% CI,63%至75%),各队列为65%至73%。
  • 总体中位缓解持续时间为16.6个月(95% CI,13.2至20.3个月),中位无进展生存期为14.7个月(95% CI,11.3至18.5个月)。
  • 70例在常规疾病进展后继续治疗的患者中,可评估者61%目标肿瘤负荷稳定或进一步缩小。
  • 最常见3至4级药物相关不良事件为脂肪酶升高(5%)、中性粒细胞减少(3%)和ALT升高(3%);共发生29例死亡,均不考虑与治疗相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) in initial analyses of one of three cohorts from the CheckMate 205 study of nivolumab for cHL. Here, we assess safety and efficacy after extended follow-up of all three cohorts. Methods This multicenter, single-arm, phase II study enrolled patients with relapsed/refractory cHL after auto-HCT treatment failure into cohorts by treatment history: brentuximab vedotin (BV)-naïve (cohort A), BV received after auto-HCT (cohort B), and BV received before and/or after auto-HCT (cohort C). All patients received nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity. The primary end point was objective response rate per independent radiology review committee. Results Overall, 243 patients were treated; 63 in cohort A, 80 in cohort B, and 100 in cohort C. After a median follow-up of 18 months, 40% continued to receive treatment. The objective response rate was 69% (95% CI, 63% to 75%) overall and 65% to 73% in each cohort. Overall, the median duration of response was 16.6 months (95% CI, 13.2 to 20.3 months), and median progression-free survival was 14.7 months (95% CI, 11.3 to 18.5 months). Of 70 patients treated past conventional disease progression, 61% of those evaluable had stable or further reduced target tumor burdens. The most common grade 3 to 4 drug-related adverse events were lipase increases (5%), neutropenia (3%), and ALT increases (3%). Twenty-nine deaths occurred; none were considered treatment related. Conclusion With extended follow-up, responses to nivolumab were frequent and durable. Nivolumab seems to be associated with a favorable safety profile and long-term benefits across a broad spectrum of patients with relapsed/refractory cHL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018. PMID: 29584546. doi:10.1200/JCO.2017.76.0793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。